UY37936A - AGENTES iARN Y COMPOSICIONES PARA INHIBIR LA EXPRESIÓN DEL RECEPTOR DE ASIALOGLICOPROTEÍNA 1 - Google Patents
AGENTES iARN Y COMPOSICIONES PARA INHIBIR LA EXPRESIÓN DEL RECEPTOR DE ASIALOGLICOPROTEÍNA 1Info
- Publication number
- UY37936A UY37936A UY0001037936A UY37936A UY37936A UY 37936 A UY37936 A UY 37936A UY 0001037936 A UY0001037936 A UY 0001037936A UY 37936 A UY37936 A UY 37936A UY 37936 A UY37936 A UY 37936A
- Authority
- UY
- Uruguay
- Prior art keywords
- agents
- expression
- inhibit
- compositions
- asgr1
- Prior art date
Links
- 230000014509 gene expression Effects 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 4
- 101150075175 Asgr1 gene Proteins 0.000 abstract 1
- 108010002913 Asialoglycoproteins Proteins 0.000 abstract 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000009368 gene silencing by RNA Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762573206P | 2017-10-17 | 2017-10-17 | |
| US201762608606P | 2017-12-21 | 2017-12-21 | |
| US201862635277P | 2018-02-26 | 2018-02-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY37936A true UY37936A (es) | 2019-05-31 |
Family
ID=66173364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001037936A UY37936A (es) | 2017-10-17 | 2018-10-17 | AGENTES iARN Y COMPOSICIONES PARA INHIBIR LA EXPRESIÓN DEL RECEPTOR DE ASIALOGLICOPROTEÍNA 1 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11492624B2 (https=) |
| EP (1) | EP3697909A4 (https=) |
| JP (2) | JP7473472B2 (https=) |
| CN (1) | CN111212909A (https=) |
| AU (1) | AU2018352379A1 (https=) |
| CA (1) | CA3079413A1 (https=) |
| TW (1) | TW201918555A (https=) |
| UY (1) | UY37936A (https=) |
| WO (1) | WO2019079294A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2018009853A (es) * | 2016-09-02 | 2018-11-09 | Arrowhead Pharmaceuticals Inc | Ligandos de direccion. |
| IL302530A (en) * | 2020-11-06 | 2023-07-01 | Arbutus Biopharma Corp | Targeted conjugates involving modified siRNA |
| CN116617390A (zh) * | 2022-02-11 | 2023-08-22 | 武汉大学 | Asgr1抑制剂在促进胆固醇外排和治疗非酒精性脂肪性肝病中的应用 |
| WO2024046297A1 (zh) * | 2022-09-02 | 2024-03-07 | 北京福元医药股份有限公司 | 抑制去唾液酸糖蛋白受体基因表达的siRNA、其缀合物和药物组合物及用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| NL9201440A (nl) | 1992-08-11 | 1994-03-01 | Univ Leiden | Triantennaire clusterglycosiden, hun bereiding en toepassing. |
| DE60040274D1 (de) | 1999-03-10 | 2008-10-30 | Phogen Ltd | Verabreichung von nukleinsäuren und proteinen an zellen |
| US8137695B2 (en) | 2006-08-18 | 2012-03-20 | Arrowhead Madison Inc. | Polyconjugates for in vivo delivery of polynucleotides |
| CN1300312C (zh) * | 2004-08-23 | 2007-02-14 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 靶向去唾液酸糖蛋白受体的抗乙型肝炎病毒反义寡核苷酸的结构和用途 |
| JP2010505897A (ja) * | 2006-10-11 | 2010-02-25 | マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ | インフルエンザターゲット |
| EP2295543A1 (en) * | 2009-09-11 | 2011-03-16 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Method for the preparation of an influenza virus |
| DK2539451T3 (da) | 2010-02-24 | 2016-04-04 | Arrowhead Res Corp | Sammensætninger til målrettet tilførsel af siRNA |
| US8501930B2 (en) | 2010-12-17 | 2013-08-06 | Arrowhead Madison Inc. | Peptide-based in vivo siRNA delivery system |
| WO2013032829A1 (en) | 2011-08-26 | 2013-03-07 | Arrowhead Research Corporation | Poly(vinyl ester) polymers for in vivo nucleic acid delivery |
| JP2015515530A (ja) | 2012-04-18 | 2015-05-28 | アローヘッド リサーチ コーポレイション | インビボ核酸送達のためのポリ（アクリラート）ポリマー |
| CA2997444A1 (en) * | 2015-09-29 | 2017-04-06 | Amgen Inc. | Asgr inhibitors for reducing cholesterol levels |
| JOP20160211B1 (ar) * | 2015-10-01 | 2021-08-17 | Arrowhead Pharmaceuticals Inc | تراكيب وأساليب لتثبيط تعبير جيني للـ lpa |
| KR102515329B1 (ko) | 2016-03-07 | 2023-03-29 | 애로우헤드 파마슈티컬스 인코포레이티드 | 치료용 화합물을 위한 표적화 리간드 |
| UY37376A (es) * | 2016-08-26 | 2018-03-23 | Amgen Inc | Construcciones de arni para inhibir expresión de asgr1 y métodos para su uso |
| MX2018009853A (es) | 2016-09-02 | 2018-11-09 | Arrowhead Pharmaceuticals Inc | Ligandos de direccion. |
-
2018
- 2018-10-16 US US16/756,440 patent/US11492624B2/en active Active
- 2018-10-16 WO PCT/US2018/056077 patent/WO2019079294A1/en not_active Ceased
- 2018-10-16 AU AU2018352379A patent/AU2018352379A1/en not_active Abandoned
- 2018-10-16 EP EP18868368.4A patent/EP3697909A4/en active Pending
- 2018-10-16 CA CA3079413A patent/CA3079413A1/en active Pending
- 2018-10-16 JP JP2020521451A patent/JP7473472B2/ja active Active
- 2018-10-16 CN CN201880066319.0A patent/CN111212909A/zh active Pending
- 2018-10-17 UY UY0001037936A patent/UY37936A/es not_active Application Discontinuation
- 2018-10-17 TW TW107136576A patent/TW201918555A/zh unknown
-
2024
- 2024-04-11 JP JP2024064086A patent/JP2024086876A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3697909A4 (en) | 2021-10-13 |
| WO2019079294A1 (en) | 2019-04-25 |
| CA3079413A1 (en) | 2019-04-25 |
| AU2018352379A1 (en) | 2020-06-04 |
| JP2024086876A (ja) | 2024-06-28 |
| CN111212909A (zh) | 2020-05-29 |
| US20200283777A1 (en) | 2020-09-10 |
| EP3697909A1 (en) | 2020-08-26 |
| JP7473472B2 (ja) | 2024-04-23 |
| TW201918555A (zh) | 2019-05-16 |
| JP2020537653A (ja) | 2020-12-24 |
| US11492624B2 (en) | 2022-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019502333A1 (en) | Targeted compositions | |
| MX2025010269A (es) | Constructos de arni para inhibir la expresion de pnpla3 y metodos de uso de los mismos | |
| CL2021001490A1 (es) | Constructos de iarn modificados químicamente y usos de estos | |
| JOP20200115A1 (ar) | تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات)) | |
| DOP2019000132A (es) | COMPOSICIONES DE ARNi DE SERPINA1 Y SUS MÉTODOS DE USO DE LAS MISMAS. | |
| BR112016029041A8 (pt) | uso de um inibidor de glutaminase, composição farmacêutica e kit farmacêutico | |
| BR112018074185A2 (pt) | 3-oxo-2,6-difenil-2,3-di-hidropiridazina-4-carboxamidas | |
| MX2019009361A (es) | Composiciones y metodos para el tratamiento de hemoglobinopatias. | |
| MX2026000462A (es) | Constructos de arni para inhibir la expresion de pnpla3 y metodos de uso de estos | |
| JOP20210043A1 (ar) | تراكيب وأساليب لتثبيط تعبير جيني للـ lpa | |
| BR112018008746A2 (pt) | composições e métodos para a inibição de atividade de arginase | |
| BR112017017727A8 (pt) | Heterociclos bicíclicos como inibidores de fgfr4 | |
| UY37936A (es) | AGENTES iARN Y COMPOSICIONES PARA INHIBIR LA EXPRESIÓN DEL RECEPTOR DE ASIALOGLICOPROTEÍNA 1 | |
| UY37800A (es) | AGENTES DE iARN PARA LA INHIBICIÓN DE LA EXPRESIÓN DE ALFA-ENaC Y MÉTODOS DE USO | |
| PE20210921A1 (es) | Agentes arni como inhibidores de la transcripcion de la serpina 1 y composiciones que los comprenden | |
| EP4219715A3 (en) | Stabilized cebpa sarna compositions and methods of use | |
| WO2019217397A3 (en) | Compositions and methods for improving strand biased | |
| PH12020550244A1 (en) | Nucleic acids for inhibiting expression of a target gene comprising phosphorodithioate linkages | |
| NZ780072A (en) | Glycotargeting therapeutics | |
| MX2024009873A (es) | Construcciones de arni para inhibir expresion de asgr1 y metodos para su uso. | |
| GEAP202115219A (en) | Pyrazole magl inhibitors | |
| WO2020104649A3 (en) | Novel rna compositions and methods for inhibiting angptl8 | |
| MX2017011298A (es) | Métodos para tratar cáncer que albergan la pérdida hemicigota de tp53. | |
| WO2016205323A8 (en) | Polynucleotide agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof | |
| MX2026000159A (es) | Construcciones de arni para inhibir la expresion de scap y metodos de uso de las mismas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 104 | Application deemed to be withdrawn (no substantive examination fee paid) |
Effective date: 20201203 |